指南与共识抗栓抗凝管理治疗药物监测与药物基因组学

基于血容量的依诺肝素剂量指南在创伤患者静脉血栓栓塞预防中的评价

Evaluation of a novel blood volume-based enoxaparin dosing guideline for venous thromboembolism prophylaxis in trauma patients.
指南 / 共识 · Am J Health Syst Pharm · 2023-01-01

本研究在大型学术一级创伤中心回顾性比较基于血容量(BV)与基于体重指数(BMI)的依诺肝素预防指南。主要结局为首次稳态抗Xa谷浓度达标率(0.2-0.5 IU/mL),BV组达标率显著高于BMI组(81% vs 62.6%,P=0.008),且BV指南是达标的唯一相关因素(调整OR=2.02,P=0.01),两组临床相关出血和VTE发生率相似。

要点

  • BV-based dosing increased target anti-Xa attainment vs BMI-based (81% vs 62.6%, P=0.008).
  • BV guideline independently associated with target anti-Xa (adjusted OR 2.02, P=0.01).
  • Bleeding and VTE rates were similar between BV and BMI groups.

核心结论

  • 使用基于血容量的依诺肝素预防剂量指南可显著提高创伤患者目标抗Xa水平达标率。

研究设计与样本

  • 回顾性前后对照研究,在大型学术一级创伤中心开展。
  • BV组依诺肝素剂量:血容量3-4.9 L者30 mg每12小时,5-6.9 L者40 mg每12小时,≥7 L者60 mg每12小时。

主要发现

  • BMI组63例(62.6%)达到目标抗Xa水平(0.2-0.5 IU/mL),BV组115例(81%),差异有统计学意义(P=0.008)。
  • 多因素回归显示,基于BV的指南是唯一与目标抗Xa达标相关的变量(调整OR=2.02;P=0.01)。
  • 两组临床相关出血和VTE发生率相似。
  • 两组中位年龄分别为38岁(BMI组)与42岁(BV组),平均BMI分别为27.4与27.7 kg/m2,平均血容量均为5.1 L。

关键数值与推荐

  • 目标抗Xa谷浓度范围为0.2-0.5 IU/mL。
  • BV剂量分层:血容量3-4.9 L予30 mg每12小时;5-6.9 L予40 mg每12小时;≥7 L予60 mg每12小时。

临床怎么用

  • 对于创伤患者,可考虑采用基于血容量的依诺肝素预防剂量方案以提高抗Xa达标率。
  • 临床相关出血和VTE发生率未因BV方案而增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fixed-dose and body mass index (BMI)-based enoxaparin regimens provide inadequate venous thromboembolism (VTE) prophylaxis for many trauma patients. The purpose of this study was to evaluate the effectiveness of a novel blood volume (BV)-based enoxaparin guideline vs a historical BMI-based guideline for VTE prophylaxis in trauma patients. METHODS: This was a retrospective pre/post study completed at a large academic level 1 trauma center. All adult trauma patients admitted from October through December 2019 and August through October 2020 who received prophylactic enoxaparin per guideline were included. The BV dosing was as follows: patients with a BV of 3 to 4.9 L received enoxaparin 30 mg every 12 hours, those with a BV of 5 to 6.9 L received 40 mg every 12 hours, and those with a BV of ≥7 L received 60 mg every 12 hours. The primary outcome was the percentage of patients who attained a target anti-factor Xa (anti-Xa) postdosing level at the first steady-state assessment (0.2 to 0.5 IU/mL). RESULTS: A total of 241 patients (99 for the BMI group and 142 for the BV group) were included. The study groups had a median age of 38 vs 42 years, a mean BMI of 27.4 vs 27.7 kg/m2, and a mean BV of 5.1 vs 5.1 L, respectively. A total of 63 patients (62.6%) in the BMI group attained target anti-Xa levels compared to 115 patients (81%) in the BV group (P = 0.008). In multivariate regression, the BV-based guideline was the only variable associated with attainment of target anti-Xa levels (adjusted odds ratio, 2.02; P = 0.01). Clinically relevant bleeding and VTE rates were similar between the groups. CONCLUSION: Dosing prophylactic enoxaparin using a BV-based dosing guideline significantly increased attainment of target anti-Xa levels.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Langenstroer EA, Carver TW, Herrmann DJ, et al. Evaluation of a novel blood volume-based enoxaparin dosing guideline for venous thromboembolism prophylaxis in trauma patients. Am J Health Syst Pharm. 2023. PMID: 37256752. doi:10.1093/ajhp/zxad119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。